Search Results

You are looking at 41 - 50 of 165 items for :

  • "early breast cancer" x
  • All content x
Clear All
Full access

Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, and for the NCCN Adjuvant Therapy for Breast Cancer Task Force

The Early Breast Cancer Trialists’ overview analysis documented that women with ER-positive breast cancer benefit from adjuvant tamoxifen by a reduction in the annual odds of recurrence or death relatively consistently across all age groups. 11 In

Full access

Harold J. Burstein

bone scans in the staging of early breast cancer at low risk for metastasis. No surveillance testing (biomarkers) or imaging (PET, CT, and radionuclide bone scans) for asymptomatic patients who have been treated for breast cancer with curative intent

Full access

Jeffrey Crawford, David C. Dale, Nicole M. Kuderer, Eva Culakova, Marek S. Poniewierski, Debra Wolff, and Gary H. Lyman

Group B trial 9741 . J Clin Oncol 2003 ; 21 : 1431 – 1439 . 14. Bonneterre J Roche H Kerbrat P . Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year

Full access

Heidi Klepin, Supriya Mohile, and Arti Hurria

older with early breast cancer . N Engl J Med 2004 ; 351 : 971 – 977 . 30 Muss HB Berry DL Cirrincione C . Standard chemotherapy (CMF or AC) versus capecitabine (X) in early-stage breast cancer patients 65 and older: results of CALGB

Full access

Megan C. Roberts, Allison W. Kurian, and Valentina I. Petkov

. 26598755 10.1200/JCO.2015.63.2489 5. de Boer RH , Baker C , Speakman D , . The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer . Med J Aust 2013 ; 199 : 205 – 208 . 10.5694/mja12.11334 6

Full access

Allan Lipton, Robert Uzzo, Robert J. Amato, Georgiana K. Ellis, Behrooz Hakimian, G. David Roodman, and Matthew R. Smith

2008 ; 39 : 1809 – 1815 . 49 Conforti R Xia W Boulet T . Cxcr4 expression and risk of bone metastasis in patients with early breast cancer [abstract] . J Clin Oncol 2007 ; 25 ( 18 Suppl ): Abstract 10610 . 50 Lipton A Chapman

Full access

Shi-Yi Wang, Tiange Chen, Weixiong Dang, Sarah S. Mougalian, Suzanne B. Evans, and Cary P. Gross

supplemental online content. References 1. Ravdin PM Siminoff LA Davis GJ . Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer . J Clin Oncol 2001 ; 19 : 980 – 991 . 2. Wishart

Full access

Min Huang, Joyce O’Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortes, Scott Ramsey, Andrew Briggs, Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, Muhan Yuan, John Cook, Michael Untch, Peter Schmid, and Peter A. Fasching

. Saad ED , Squifflet P , Burzykowski T , . Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta

Full access

D. Craig Allred, Robert W. Carlson, Donald A. Berry, Harold J. Burstein, Stephen B. Edge, Lori J. Goldstein, Allen Gown, M. Elizabeth Hammond, James Dirk Iglehart, Susan Moench, Lori J. Pierce, Peter Ravdin, Stuart J. Schnitt, and Antonio C. Wolff

References 1 Early Breast Cancer Trialists’ Collaborative Group . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials . Lancet 2005 ; 365

Full access

Zachary Veitch, Omar F. Khan, Derek Tilley, Patricia A. Tang, Domen Ribnikar, Douglas A. Stewart, Xanthoula Kostaras, Karen King, and Sasha Lupichuk

Background Treatment of early-stage breast cancer with adjuvant chemotherapy has improved survival. Landmark meta-analyses by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) initially showed a 20% to 25% relative risk reduction in